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Abstract
Background: Ribonucleases are promising agents for use in anticancer therapy. Among the different ribonucleases
described to be cytotoxic, a paradigmatic example is onconase which manifests cytotoxic and cytostatic effects,
presents synergism with several kinds of anticancer drugs and is currently in phase II/III of its clinical trial as an
anticancer drug against different types of cancer. The mechanism of cytotoxicity of PE5, a variant of human
pancreatic ribonuclease carrying a nuclear localization signal, has been investigated and compared to that of
onconase.
Methods: Cytotoxicity was measured by the MTT method and by the tripan blue exclusion assay. Apoptosis was
assessed by flow cytometry, caspase enzymatic detection and confocal microscopy. Cell cycle phase analysis was
performed by flow cytometry. The expression of different proteins was analyzed by western blot.
Results: We show that the cytotoxicity of PE5 is produced through apoptosis, that it does not require the
proapoptotic activity of p53 and is not prevented by the multiple drug resistance phenotype. We also show that
PE5 and onconase induce cell death at the same extent although the latter is also able to arrest the cell growth.
We have compared the cytotoxic effects of both ribonucleases in the NCI/ADR-RES cell line by measuring their
effects on the cell cycle, on the activation of different caspases and on the expression of different apoptosis- and
cell cycle-related proteins. PE5 increases the number of cells in S and G2/M cell cycle phases, which is
accompanied by the increased expression of cyclin E and p21
WAF1/CIP1 together with the underphosphorylation of
p46 forms of JNK. Citotoxicity of onconase in this cell line does not alter the cell cycle phase distribution and it is
accompanied by a decreased expression of XIAP
Conclusions: We conclude that PE5 kills the cells through apoptosis associated with the p21
WAF1/CIP1 induction
and the inactivation of JNK. This mechanism is significantly different from that found for onconase.
Background
Members of the pancreatic ribonuclease (RNase) super-
family display an array of biological activities ranging
from cytotoxicity to angiogenesis. Among them, cyto-
toxicity is one of the most attractive since such enzymes
could be used, alone or conjugated to ligands or antibo-
dies, as non-mutagenic therapeutic agents for cancer
treatment (for a review, see [1]). Among the different
natural or engineered RNases described to be cytotoxic,
the case of onconase, a monomeric RNase isolated from
Rana pipiens (northern leopard frog), is paradigmatic.
This drug manifests cytotoxic and cytostatic effects [2],
presents synergism with several kinds of anticancer
drugs (for a review, see [3]), and is currently in phase
II/III of clinical trial as an anticancer drug against differ-
ent types of cancer [4]. Ribonucleolytic activity of onco-
nase, exerted in vivo in the cytoplasm, is essential for its
cytotoxicity [5]. Its natural substrates are t-RNA and
most probably the non-coding RNA (microRNA) that is
involved in regulation of gene expression through RNA
interference (for a review, see [3]). Indeed, it has been
postulated that the observed synergisms of this RNase
may be a consequence of onconase targeting specifically
the family of microRNA shown to enhance tumor resis-
tance to cytotoxic anticancer therapy by mobilizing the
cell defense mechanisms [6]. Onconase, nevertheless,
shows renal toxicity at high concentrations [7,8].
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as the human pancreatic RNase (HP-RNase) would
undoubtedly provide a potentially useful therapeutic
agent which would be expected to have lower immuno-
genicity and renal toxicity than onconase.
Several variants of HP-RNase have been described as
cytotoxic (for a review see [1]) and most of them are
resistant to the cytosolic RNase inhibitor (RI). HP-RNase
does not show renal accumulation in vivo [7,8] and pre-
sents around 10
3-10
4 times higher ribonucleolytic activity
compared to onconase [9]. We have reported a cytotoxic
variant of HP-RNase, named PE5, which, despite being
sensitive to the RI, is cytotoxic for a panel of diverse cell
lines [10]. Nuclear import assays showed that PE5 was
efficiently transported to the nucleus where it was initi-
ally localized in the nucleolus. The variant carries a con-
formational bipartite nuclear localization signal [11]
which targets the protein to the nucleus, specifically in
the nucleolus [10], where RI is absent, therefore produ-
cing the degradation of nuclear RNA [12].
In the present work we have observed that one of the
cell lines most sensitive to the action of PE5 is NCI/
ADR-RES. This ovarian cancer cell line is representative
of poor-prognosis ovarian cancer. It is worth mentioning
that ovarian carcinoma is the deadliest gynecologic
malignancy and the fifth leading cause of death due to
cancer in women in the United States [13]. Because
ovarian cancer is often diagnosed only after the disease
has reached an advanced stage, the majority of patients
require additional treatment after surgical removal of
the tumor. Aggressive surgical debulking and platinum
plus taxane therapy have improved median survival
from one year in 1975 to approximately five years in
2005, but the long-term cure rate continues to languish
in the 20% to 30% range [14] because most cases ulti-
mately develop resistance. Approximately 50% of the
patients will enter a first complete clinical remission, yet
90% of suboptimally debulked patients and 70% of opti-
mally debulked patients relapse in 18 to 24 months. For
this reason, novel approaches are being sought to over-
come chemoresistance and develop more effective thera-
pies. Currently, biological therapies are being considered
as the next approach in the fight against ovarian cancer.
These therapies have the potential to selectively target
tumors, to minimize toxicity, and to overcome the resis-
tance often observed with conventional therapies [15].
Since PE5 is directed to the nucleus where it degrades
nuclear RNA [12] while onconase displays its activity
degrading cytosolic RNA, we sought to compare the
cytotoxic properties of bothR N a s e so nt h i sN C I / A D R -
RES cell line. We also wanted to check whether this
RNase could be a candidate to have its antitumor prop-
erties evaluated in vivo. For this, we were interested in
investigating the selectivity of PE5 against tumor cells
lines and to determine whether this RNase kills the cells
through induction of apoptosis.
Methods
Ribonuclease expression and purification
Construction of plasmids expressing onconase (pONC)
and PE5 (pPE5) have been previously described
[10,16,17]. PE5 was constructed from PM5 replacing
G89 and S90 by arginine [10]. PM5 codes for HP-RNase
and incorporates the substitutions R4A K6A Q9E D16G
and S17N [17]. Recombinant onconase and PE5 were
produced and purified from E. coli BL21 (DE3) cells
transformed with the corresponding vector essentially as
described previously [18,19]. Briefly, frozen pellets from
2 L of induced culture were resuspended in 30 ml of 50
mM Tris-HCl, (pH 8.0), 10 mM EDTA. Cells were lysed
using a French press and inclusion bodies were har-
vested by centrifugation. Pellets were then resuspended
in 10 ml of 6 M guanidinium-HCl, 10 mM EDTA, 50
mM Tris-acetate, (pH 8.0). Reduced glutathione was
added to a final concentration of 0.1 M, the pH was
adjusted to 8.5 with solid Tris, and the samples were
incubated at room temperature for 2 h under nitrogen
atmosphere to assist protein solubilization. Insoluble
material was removed by centrifugation and solubilized
protein was diluted dropwise into 0.5 M L-arginine,
1 mM oxidized glutathione, 2 mM EDTA, 0.1 M Tris-
acetate, (pH 8.5), and incubated at 4°C for at least 24 h.
To stop oxidation, the pH was then lowered to 5 with
acetic acid and the proteins were concentrated by ultra-
filtration using a Prep/Scale TFF cartridge (Millipore,
Bedford, MA, USA). In the case of onconase, cyclization
of the N-terminal Gln residue to pyroglutamic acid is
essential for its full catalytic activity and its cytotoxic
properties. This is accomplished at this step by dialysis
against 200 mM sodium phosphate (pH 7.2) at room
temperature for a period of 48 h [19]. Both onconase
and HP-RNase variants were then dialyzed against
50 mM sodium acetate (pH 5). Precipitated or insoluble
material was eliminated by centrifugation, and the sam-
ple was loaded onto a Mono-S HR 5/5 FPLC column
(Amersham Biosciences, Piscataway, NJ, USA). Fractions
containing pure RNases were dialyzed against water, lyo-
philized and stored at -20°C. A yield of 15-20 mg of
protein per 1 L of culture was obtained. The molecular
mass of each variant was confirmed by matrix-assisted
laser desorption/ionization time-of-flight mass spectro-
metry in the “Unitat cientificotècnica de suport“ of the
Institut de Recerca of the Hospital Universitari Vall
d’Hebron (Barcelona, Spain). The protein concentration
of each variant was determined by UV spectroscopy
using an extinction coefficient of ε278 =7 9 5 0M
-1 cm
-1
for PE5 and of ε278 = 10470 M
-1 cm
-1 for onconase, cal-
culated using the method devised by Pace et al. [20].
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NCI/ADR-RES ovarian cancer cells (formerly MCF-7/
Adr) were a generous gift from Institut Català d’Oncolo-
gia de Girona, Hospital Universitari de Girona Dr. Josep
Trueta (Girona, Spain); HeLa cervical cancer cells and
normal human fibroblasts N1 were obtained from
Eucellbank (Universitat de Barcelona, Barcelona, Spain).
Cells were routinely grown in Dulbecco’sm o d i f i e d
Eagle’s medium (Gibco, Berlin, Germany) supplemented
with 10% fetal bovine serum (FBS, Gibco, Berlin, Ger-
many), 50 U/ml penicillin and 50 μg/ml streptomycin
(Gibco, Berlin, Germany) and were maintained at 37°C
in a humidified atmosphere of 5% CO2. NCI/ADR-RES
cells were maintained in a complete Dulbecco’s modified
Eagle’s medium containing 1 μg/ml doxorubicin (Tedec-
Meijic Farma, Madrid, Spain). Cells remained free of
Mycoplasma and were propagated in adherent culture
according to established protocols.
Cell proliferation assay
Cells were seeded into 96-well plates at the appropriate
density, i. e., 7000 (for NCI/ADR-RES), 2200 (for HeLa)
and 3000 (for N1) cells. After 24 h incubation, cells
were treated with various concentrations of PE5 (0,1-30
μM) or onconase (0,001-10 μM) for 72 h. In separate
experiments, cells were treated with SP600125 (0.1-80
μM diluted in dimethyl sulfoxide (DMSO)) or DMSO
alone for 96 h. Media with either SP600125 or vehicle
were replaced every 36 h. Drug sensitivity was deter-
mined by the MTT method essentially as described by
the manufacturer’s instructions (Sigma, St. Louis, MO,
USA). Data were collected by reading at 570 nm with a
multi-well plate reader (Anthos Labtec, Cambridge, UK).
The IC50 value represents the concentration of the
assayed enzyme required to inhibit cell proliferation by
50% respective to cells treated with the carrier and in
each case was calculated by linear interpolation from
growth curves obtained.
Analysis of cytostatic and cytotoxic effects of PE5 and
onconase
NCI/ADR-RES cells (55000 per well) were seeded into
24-well plates and then treated with different concentra-
tions of PE5 (2-35 μM) or onconase (0.3-5 μM) for 24,
48 and 72 h. After treatment, attached and floating cells
were harvested and washed in cold phosphate buffered
saline (PBS). The proliferation rate and viability in con-
trol and RNase-treated cultures was estimated by cell
count using a hemocytometer combined with the trypan
blue exclusion assay.
Cell cycle phase analysis
Cell cycle phase analysis was performed by propidium
iodide (PI) staining. NCI/ADR-RES cells (1.2 × 10
6 cells/
100-mm dish) were treated with 35 μMP E 5o r1a n d
5 μM onconase for 72 h. Attached and floating cells
were then harvested and fixed with 70% ethanol for at
least 1 h at -20°C. Fixed cells were harvested by centri-
fugation and washed in cold PBS. These collected cells
were resuspended in PBS (1-2 × 10
6/ml) and treated
with RNase A (100 μg/ml) and PI (40 μg/ml) (Molecular
Probes, Eugene, OR, USA) at 37°C for 30 min prior to
flow cytometric analysis. A minimum of 10,000 cells
within the gated region were analyzed on a FACSCali-
bur flow cytometer (BD Biosciences, San Jose, CA,
USA). Cell cycle distribution was analyzed using the
FlowJo program (FreeStar, Ashland, OR, USA).
Apoptotic morphology analysis
Experiments were carried out in serum-starved medium,
at 37°C and in a 5% CO2 atmosphere. NCI/ADR-RES
cells (2.2 × 10
3 per well) were treated with 35 μMP E 5
or 5 μM onconase for 72 h followed by the addition of
4 μM calcein AM and 20 μg/ml PI (Molecular Probes,
Eugene, OR, USA). The effect of PE5 and onconase was
analyzed using a laser scanning confocal microscope
(Leica, Wetzlar, Germany). Images of cells stained with
calcein AM and PI were acquired using a 488-nm argon
laser and a 561-nm HeNe laser, respectively.
NCI/ADR-RES cells (2.2 × 10
4 per well) were also
seeded in 35-cm
2 plates with a glass coverslip and trea-
ted with 35 μM PE5 or 5 μM onconase. After 72 h cells
were incubated with 0.5 μg/ml Hoechst 33342 (Molecu-
lar Probes, Eugene, OR, USA) for 30 min at 37°C in the
dark. Confocal images of the cultures were captured
using a laser scanning confocal microscope and a 405-
nm blue diode laser.
Phosphatidylserine exposure assay
Quantitative analysis of apoptotic cell death caused by
PE5 and onconase treatment was performed by flow
cytometry using the Alexa Fluor 488 annexin V/PI
Vybrant Apoptosis Assay Kit (Molecular Probes, Eugene,
OR, USA) following the manufacturer’si n s t r u c t i o n s .
Briefly, NCI/ADR-RES cells (2.2 × 10
5 per well) were
seeded into 6-well plates and then treated with 35 μM
PE5 or 5 μM onconase for 24, 48 and 72 h in serum-
starved medium. After treatment, attached and floating
cells were harvested, washed in cold PBS and subjected
to Annexin V-Alexa Fluor 488 and PI staining in bind-
ing buffer at room temperature for 15 min in the dark.
Stained cells were analyzed on a FACSCalibur flow cyt-
ometer using CellQuest Pro software. A minimum of
10,000 cells within the gated region were analyzed.
Caspase activation assay
Caspase-3, -8 and -9 catalytic activities were measured
using the APOPCYTO Caspase-3, -8 and -9 colorimetric
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turer’s protocol. The assay is based on cleavage of the
chromogenic substrates, DEVD-pNA, IETD-pNA and
LEHD-pNA, by caspases-3, -8 and -9, respectively.
Briefly, NCI/ADR cells (1.2 × 10
6 cells/100-mm dish)
were incubated with 35 μMP E 5o r5μM onconase for
24, 48 and 72 h in serum-starved medium. Then,
attached and floating cells were lysed and centrifuged.
The supernatant was recovered, and the protein concen-
tration was determined using the Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Afterwards,
50 μl of the cell lysate corresponding to 110 μgo ft o t a l
protein, 50 μl of 2X reaction buffer containing 10 mM
DTT and 5 μl of the 10 mM DEVD-pNA, IETD-pNA or
LEHD-pNA substrates were added to each well of the
96-well plates. To confirm the specific hydrolysis of sub-
strate, samples were treated with the caspase inhibitors
DEVD-FMK, IETD-FMK or LEHD-FMK, which are spe-
cific inhibitors of caspases-3, -8 and -9, respectively, fol-
lowing the manufacturer’s protocol. Then the plate was
incubated at 37°C for 4 hours. The reaction was mea-
sured by changes in absorbance at 405 nm.
Western blot analysis
NCI/ADR-RES cells (1.2 × 10
6 cells/100-mm dish) were
incubated with 7 μMP E 5o r1a n d5μMo n c o n a s ef o r
72 h, harvested with trypsin-EDTA solution and washed
in cold PBS. Cells were lysed in lysis buffer (Cell Signal-
ling Technology, Beverly, MD, USA) and a sample was
taken to measure protein content using the Bradford
protein assay. Protein samples were separated on a
12.5% SDS-PAGE gel and transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, MA, USA).
The membranes were incubated for 1 h at room tem-
perature in blocking buffer [3% powdered-skim milk in
TBS-T (10 mM Tris-HCl (pH 7.5), 100 mM NaCl and
0.1% Tween-20)] to prevent non-specific antibody bind-
ing. Antibody dilution was prepared in blocking buffer
and blots were incubated with monoclonal antibody
overnight at 4°C. Antibodiesa g a i n s tB c l - 2( #s c - 7 3 8 2 ,
1:200 dilution), Bax (# sc-7480, 1:1000 dilution), Cyclin
D1 (# sc-20044, 1:1000 dilution), Cyclin E (# sc-247,
1:1000 dilution), p27 (# sc-1641, 1:200 dilution), JNK (#
sc-7345, 1:50 dilution), p-JNK (# sc-6254, 1:1000 dilu-
tion) were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The antibodies against JNK and phosphory-
lated JNK recognize JNK1, JNK2 and JNK3; however
JNK3 is not expressed in ovarian cells. Antibodies
against GAPDH (Chemicon/Millipore, Billerica, MA,
USA, mAB374, 1:12000000 dilution) and XIAP (BD
Transduction Laboratories, San Jose, CA, USA #
610716, 1:1000 dilution) were also used. Afterwards,
membranes were incubated for 1 h at room temperature
with anti-mouse horseradish peroxidase-conjugated
secondary antibody (dilution 1:30000) (Calbiochem, La
Jolla, CA, USA). Blots were developed with immobilon
chemiluminescent HRP substrate (Millipore, Bedford,
MA, USA) and images were captured by a FluorChem
SP system (Alpha Innotech, San Leandro, CA, USA).
Quantity analysis is based on the intensity of the band
using the Quantity One software (Bio-Rad Laboratories,
Hercules, CA, USA). The linearity of the assay was preli-
minarily checked for each monoclonal antibody by sub-
mitting different amounts of untreated cell extracts to
western blotting.
Statistical analysis
R e s u l t sw e r ea n a l y z e db yo n e - w a yA N O V Ao rb y
repeated-measures ANOVA using a Sidak test as a post-
test. P-values below 0.05 were considered statistically
significant. All data are described as the mean ± stan-
dard error (SE). All observations were confirmed by at
least three independent experiments.
Results
Cytotoxicity studies
PE5 is cytotoxic for NCI/ADR-RES and HeLa cell lines
using the MTT assay. For comparison, this experiment
was also performed with onconase. The results indicated
that PE5 was seven- to ten-fold less cytotoxic than
onconase in both cases (Table 1). We also examined the
cytotoxic effect of these RNases on N1 normal human
fibroblasts. Again, both RNases were cytotoxic for N1
fibroblasts. However, in this case the difference in IC50s
between both RNases was increased to nearly 20-fold
(Table 1).
The MTT assay does not allow discerning whether the
drug exerts a cytostatic or a cytotoxic effect and there-
fore we investigated the effect of both proteins on cell
growth and cell viability. We focused this study on the
NCI/ADR-RES cell line because it was the most sensi-
tive to PE5. Figure 1 shows the effect on NCI/ADR-RES
proliferation and viability of incubating four different
concentrations of PE5 or onconase for up to 72 h. Even
at 24 h of intoxication an effect of both RNases on pro-
liferation could be observed at the highest concentra-
tions assayed. At this same time the viability of NCI/
ADR-RES cells was reduced only by treatment with 14
or 35 μM PE5. Consistently with the cytotoxicity results
Table 1 IC50 values for PE5 and onconase for the
indicated cell lines
Cell line PE5 (μM) Onconase (μM)
HeLa 8.2 ± 0.6 0.8 ± 0.1
NCI/ADR-RES 6.9 ± 0.8 1.1 ± 0.1
N1 19.5 ± 1.4 1.0 ± 0.2
Data are presented as mean ± SE of at least three independent experiments
made in triplicates.
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nase for 72 h (which correspond to the IC50 values
described in Table 1) decreased the proliferation to
around 50% respective to untreated cells (Figures 1A
and 1B). Therefore, PE5 is mainly cytotoxic although at
low concentrations a minimal cytostatic effect can be
observed. On the contrary, onconase arrests prolifera-
tion at low concentrations (below to 1 μM) but begins
to be cytotoxic at higher concentrations, as it has been
previously described for other cell lines [2]. Interestingly,
although a seven-fold lower concentration of onconase
was necessary to reduce cell growth to 50%, the percen-
tage of viable cells at each incubation time was similar
when using either PE5 or onconase. This shows that
b o t hR N a s e si n d u c ec e l ld e a t ha tt h es a m ee x t e n tb u t
that onconase presents an additional capacity of arrest-
ing cell proliferation.
Analysis of the PE5 treatment on the cell cycle phase
distribution
We investigated the effect of 35 μM PE5 on the NCI/
ADR-RES cell cycle progression (Figure 2). For compari-
son, the effect of 5 μM onconase on the cell cycle phase
distribution was also investigated. After 72 h of PE5
exposure, a clear increase of S and G2/M cell cycle
phases, concomitant with a decrement of G0/G1 cell
cycle phase cells was observed. In contrast, the cell cycle
phase distribution of cells treated with a cytotoxic con-
centration of onconase was very similar to that of
untreated growing cells. In both cases, a significant pro-
portion of RNase-treated cells were identified as a sub-
G1 cell population which corresponds to apoptotic cells
carrying fractional DNA.
To further characterize the effect of PE5 on the cell
cycle phase distribution we used western blot to also
analyze the expression of cyclin D1, cyclin E, p21
WAF1/
CIP1 and p27
KIP1 (Figure 3). PE5 increased the expres-
sion of cyclin E to a 209% ± 25 of that of untreated
cells and also that p21
WAF1/CIP1 to a minor extent (to
175% ± 37 of untreated cells). The amounts of cyclin
D1 and of p27
KIP1 remained nearly unchanged respec-
tive to untreated cells.
PE5 induces apoptosis in NCI/ADR-RES cells
We studied the cell death induced by the treatment with
PE5 and whether the RNase-treated cells displayed char-
acteristic features of apoptosis. Onconase was included
as a control in these experiments since it has been
shown that it induces apoptosis in different cell lines
(for a review, see [21]). NCI/ADR-RES cells were treated
with 35 μM PE5 or 5 μM onconase for 72 h, stained
with Hoechst 33342 and then analyzed, using a confocal
Figure 1 Proliferation and viability curves of NCI/ADR-RES cells treated with PE5 or onconase. Cells were treated with 0 (black circle), 2
(white circle), 7 (black triangle), 14 (white triangle) and 35 μM (black square) of PE5 (A and C) or 0 (black circle), 0.3 (white circle), 1 (black
triangle), 2 (white triangle) and 5 μM (black square) of onconase (B and D). Trypan blue dye exclusion cell viability was estimated at 0, 24, 48
and 72 h after administration of the RNases. The plotted points represent means of at least three independent experiments.
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control cells, nuclear morphological changes typical of
apoptosis, such as the characteristic chromatin conden-
sation and the nuclear fragmentation, could be observed
( F i g u r e4 ) .T h eP E 5a n do n c o n a s ee f f e c to nN C I / A D R -
RES cell morphology was also studied in fresh cultures
using calcein AM and PI staining. Cells treated with 35
μMP E 5o r5μM onconase show typical apoptosis fea-
tures like membrane blebbing, apoptotic body forma-
tion, chromatin condensation and apoptotic nuclear
fragmentation (Figure 4).
We sought to quantify the percentage of NCI/ADR-
RES cells in early and late apoptosis after 24, 48 and 72
h of incubation with 35 μM PE5. As a control, the same
experiment was performed with 5 μMo n c o n a s e .T h e
results of the FACS analysis of these cells, stained with
Annexin V-Alexa Fluor 488 and PI, show that the per-
centage of necrosis induced by the treatment was negli-
gible in both cases (Table 2). Again, induction of
apoptosis could be demonstrated by the translocation of
phosphatidylserine to the external hemi-membrane.
Apoptosis was evident at 48 h of treatment in both
cases and further increased at 72 h. Interestingly, the
percentage of cells treated with PE5 that were at early
apoptosis was nearly 50% higher than that of those trea-
ted with onconase.
The mechanisms of apoptosis of PE5 and onconase are
different
We were interested in investigating whether the cyto-
toxic mechanism of both RNases could be different. In
order to characterize apoptosis of NCI/ADR-RES cells
induced by PE5 and onconase, activation of procas-
pases-3, -8 and -9 was investigated (Figure 5). PE5
induces the activation of the procaspases-3 and -8 even
at 24 h of drug incubation (p < 0.05). Activation reaches
its maximum at 48 h. Activation of procaspase-9 is also
induced by PE5 but it can be only detected after 48 h of
incubation with the RNase and continues to increase at
72 h. For onconase, procaspase-8 and -9 activation was
delayed to 48 h of RNase incubation (p < 0.05). The pat-
tern of activation is very similar to that found for PE5.
At 72 h of incubation with onconase the three caspases
were active although to a minor extent when compared
to PE5 treatment. Caspase activity was also investigated
after 72 h of RNase incubation in the presence of the
caspase-specific inhibitors DEVD-FMK, IETD-FMK or
LEHD-FMK. In the presence of these inhibitors the
activity dropped to the level of the control extracts.
We investigated by western blot the effect produced
by PE5 on the level of different apoptosis-related pro-
teins. Cellular extracts from NCI/ADR-RES treated for
7 2hw i t h7μM PE5 were subjected to immunoblotting
using antibodies against Bcl-2, Bax, XIAP, JNK and the
phosphorylated form of p46JNK. For comparison, addi-
tional experiment incubating NCI/ADR-RES with 5 μM
onconase were performed.
We show in Figure 6 the effects of the treatment of
NCI/ADR-RES with either PE5 or onconase on the
expression of these apoptotic-related proteins. PE5 did
not change the expression levels of any of the assayed
proteins. However, it induced a clear decrease of the
level of the phosphorylated form of p46 JNK respective
to untreated cells (two-fold decrease). For onconase,
important differences could be detected when compared
with PE5. In this case, the levels of Bax, Bcl-2 and JNK
remained unaltered compared to untreated cells but a
clear decrease of XIAP was observed. On the other
hand, we could not detect changes in the levels of phos-
phorylated form of JNK respective to untreated cells.
Figure 2 Effects of PE5 and onconase on the NCI/ADR-RES cell cycle phase distribution after treatment for 72 h. Untreated cells (A), 35
μM PE5 treated cells (B) and 5 μM onconase treated cells (C) were permeabilized and stained with PI. Cell DNA content was analyzed by flow
cytometry. Data are representative of three independent assays. Values were analyzed from 10,000 total events.
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induced apoptosis it has been postulated that JNK exerts
an anti-apoptotic activity in p53-deficient tumor cells
[22]. We therefore tested whether SP600125, a known
inhibitor of JNK [23], could produce a cytotoxic effect
on NCI/ADR-RES cells. As expected, SP6000125 was
cytotoxic to NCI/ADR-RES cells being its IC50 after
96 h of exposure of 56.3 ± 2.1 μM (results not shown).
Discussion
Although HeLa cell line has wild type p53 alleles, it has
been reported [24] that it contains no detectable p53
tumor suppressor protein. NCI/ADR-RES contains
mutated p53 and, unlike the HeLa cell line, overex-
presses P-gp and GST-π multidrug resistance proteins
[ 2 5 - 2 7 ]a n da l s oX I A Pa n ds u r v i v i na n t i - a p o p t o t i cp r o -
teins [28]. Both cell lines were similarly sensitive to PE5
showing that the cytotoxicity of this RNase is not pre-
vented by a mutated p53 or multidrug resistance pheno-
types. Both cell lines were also very affected by
onconase. This was expected since it was previously
reported that onconase induces cell death in other MDR
cell lines and that the proapoptotic activity of p53 is not
required for onconase-induced apoptosis [29].
We observed that N1 cells treated with PE5 were
clearly less affected than those treated with onconase.
This is indicative that the specificity of PE5 for tumor
cells could be almost equal to that of onconase.
Although in vivo onconase presents clear anti-tumor
activity, the cytotoxicity of this RNase for non-tumor
cell lines has been described to be variable. For example,
Haigis and coworkers [30] reported the cytotoxicity of
onconase for different tumor and non-tumor cell lines.
They found that the IC50 of IMR-90 lung fibroblast cell
Figure 3 Expression of cyclin D1, cyclin E, p21
WAF1/CIP1 and
p27
KIP1 in 7 μM PE5-treated cells. 72 h after the treatments, cells
were harvested and analyzed by Western blot using the antibodies
described in the Methods section. A) Western blot of a
representative experiment. B) Densitometric analysis of the GAPDH-
normalized immunoblots of each treatment respective to that of
untreated cells. White bars indicate untreated cells (control) and
black bars indicate PE5-treated cells.
Figure 4 Nuclear and cellular morphological effects of PE5 and
onconase on the NCI/ADR-RES cell line. Overnight serum-starved
NCI/ADR-RES cells were treated with 35 μM PE5 or 5 μM onconase
for 72 h. Subsequently, Hoechst 33342 and calcein/PI staining were
performed and observed under a confocal laser microscope. Bar
50 μm.
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IC50 of WI-38 lung fibroblasts increased ten-fold.
PE5-treated cells display classical hallmarks of apopto-
sis. This is very interesting since a non-apoptotic mode
of cell death could hamper the potential application of
PE5 as an anticancer drug. As expected, onconase also
induces the apoptosis in NCI/ADR-RES, as it has been
previously reported for different cell lines (for a review,
see [4]). Both RNases induce the activation of initiation
of procaspases-8 and -9 which lead to the activation of
executioner procaspase 3 in NCI/ADR-RES cells.
Furthermore, no changes in the proportion of Bcl-2
amounts respective to those of Bax are detected in both
cases. These results suggest that the treatment of NCI/
ADR-RES with PE5 or onconase induces both extrinsic
and intrinsic apoptotic pathways, the latter being inde-
pendent of Bcl-2 and Bax. The mode by which onconase
induces cell death has been shown to be dependent on
the cell line used in the study. Onconase has been
shown to induce apoptosis by activating caspases and
serine proteases in some cases [29,31] but, recently,
onconase-induced caspase-independent death of neuro-
blastoma cell lines have been reported [32]. Although
processing of procaspases-9, -3, and -7 but not of pro-
caspase-8 has been described [29], it is not clear to what
extent the mitochondrial apoptotic pathway is involved
since no cytochrome C release or sustained decrease of
Bax has been observed [29]. In contrast, for the HL-60
human promyelocytic leukemia cell line, onconase
induced the expression of Bax while decreasing that of
Bcl-2 [33].
During apoptosis cell cycle progression is stopped
[34]. The FACSCalibur flow cytometric analysis shows
that cell death induced by PE5 is accompanied by an
accumulation of cells in the S- and G2/M-phases in the
NCI/ADR-RES cell line. This may indicate that PE5
arrest cell cycle at S- and G2/M-phases or, alternatively,
that there is preferential PE5-induced cell death in G1
cell-cycle phase, which leads a proportionally higher
percentage of S and G2/M. Over-expression of cyclin E
and p21
WAF1/CIP1 explains the observed reduction of the
percentage of cells in G0/G1 cell-cycle phase together
with the increase of the percentage of cells in S and G2/
M cell-cycle phase. Cyclin E is a G1 cyclin expressed
near the G1 to S transition and drives entry into the S
phase by binding to CDK2. Increase of cyclin E after S
or G2/M arrest has been already observed in different
works [35,36]. p21
WAF1/CIP1 acts as a dual inhibitor of
cyclin-dependent kinases (CDKs) [37] and proliferating-
cell nuclear antigen [38]. As a cyclin-dependent kinase
inhibitor, p21
WAF1/CIP1 interacts with several cyclins and
CDKs leading to inhibition of these kinases with subse-
quent cell cycle arrest. Overexpression of p21
WAF1/CIP1
results in G1-, G2- [39] or S-phase arrest [40]. Interest-
ingly, it has been described [39] that the presence of
functional pRb correlates with preponderant G1 arrest
in response to overexpression of p21
WAF1/CIP1 whereas
G2 arrest is more prominent in pRb-negative cells, as is
the case of NCI/ADR-RES [41]. As a proliferation inhi-
bitor, p21
WAF1/CIP1 is poised to play an important role
in preventing tumor development. For example, it has
been show that celecoxib leads to up-regulation of
p21
WAF1/CIP1 along with down-regulation of cyclin B1
promoting G2/M arrest and induction of apoptosis in a
p53-independent pathway [42]. Histone deacetylase inhi-
bitor trichostatin A induces p21
WAF1/CIP1, cell cycle
arrest, and apoptosis in human gastric and oral carci-
noma cell lines [43]. Pioglitazone, a peroxisome prolif-
erator-activated receptor-g agonist, induced p21
WAF1/
CIP1 and enhanced the sensitivity of carcinoid cells to
apoptosis induced by the TRAIL ligand. Adenovirus-
mediated overexpression of p21
WAF1/CIP1 in these cells
significantly enhanced the level of TRAIL-induced apop-
tosis [44]. Overexpression of p21
WAF1/CIP1 in the p53-
deficient human ovarian carcinoma cell lines SKOV3
and OVCAR3 also led to increased apoptosis in
response to cisplatin treatment [45].
Our results suggest that the apoptosis induced by PE5
is mediated through p21
WAF1/CIP1 and JNK. It has been
shown that p21
WAF1/CIP1 acts as a non-enzymatic inhibi-
tor of stress activated protein kinases (SAPKs)/JNKs
[46]. Accordingly, JNK is underphosphorylated in PE5-
treated cells. Although JNK has been implicated largely
in stress-induced apoptosis, under some circumstances,
JNK plays a protective role and supports cell survival,
and evidence is accumulating that JNK plays a role in
Table 2 Apoptosis measured by Annexin V-Alexa Fluor 488/PI staining
Control PE5 Onconase
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
Early apoptotic cells (%) 4.1 ± 0.2 4.2 ± 0.5 4.5 ± 0.7 3.9 ± 0.1 17.7 ± 1.9 28.3 ± 1.3 6.8 ± 2.1 11.9 ± 1.1 20.4 ± 2.0
Late apoptotic cells (%) 5.9 ± 0.2 7.2 ± 0.9 5.7 ± 0.1 0.7 ± 0.3 6.5 ± 1.4 26.0 ± 4.4 2.3 ± 0.1 11.6 ± 2.6 25.9 ± 1.4
Necrotic cells (%) 2.4 ± 0.3 2.4 ± 0.7 1.6 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Viable cells (%) 87.6 ± 0.6 86.2 ± 1.1 88.2 ± 1.0 95.4 ± 0.4 75.8 ± 0.5 45.7 ± 5.3 90.9 ± 2.0 76.5 ± 3.7 53.7 ± 0.6
NCI/ADR-RES cells were treated with 35 μM PE5 or 5 μM onconase for 24, 48 and 72 h, stained with Annexin V-Alexa 488 and PI and analyzed by flow cytometry.
Cells undergoing early apoptosis were positive for Annexin V and negative for PI (Annexin V+/PI-), late apoptotic cells were Annexin V+/PI+ and necrotic cells
were Annexin V-/PI+. All data were expressed as mean ± SE of three different experiments. Values were analyzed from 10,000 total events.
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gression[22]. The anti-apoptotic function of JNK has
been related to the status of p53, exerting its anti-
apoptotic activity in p53-deficient tumor cells [22]. The
p21
WAF1/CIP1 mediated inhibition of JNK in PE5 treated
cells would promote the apoptosis of NCI/ADR-RES
cells. Similar examples of induction of apoptosis by JNK
inhibition have been previously reported. For example,
treatment with antisense oligonucleotides to JNK2 and,
to a lesser extent, to JNK1, suppresses growth and
induces apoptosis of tumor cell lines with mutant but
not wild-type p53 [47]. It has been also reported that
the pharmacological inhibition of JNK using SP600125
is associated with an increase in the G2/M cell-cycle
phase and apoptosis in different cell lines [48,49] being
some of them (MCF-7 and Sk-Br-3) sensitive to PE5
( C a s t r oe ta l . ,u n p u b l i s h e dd a t a ) .F i n a l l y ,i th a sb e e n
shown [50] that cells immortalized via retrovirus-
mediated transfer of E6 HPV gene product, which tar-
gets p53 for degradation, are more sensitive to onconase
when both JNK1 and JNK2 alleles are disrupted.
Accordingly, we also show that the pharmacological
inhibition of JNK with SP600125 also produces a cyto-
toxic effect in NCI/ADR-RES cells.
Regarding onconase, we show that it does not arrest
the proliferation at a defined cell cycle phase. Although
a general consensus in the literature indicates that onco-
nase arrests proliferation at the G0/G1 cell cycle phase
[3], this is far from always being the rule. Onconase
arrests NIH/3T3 cells at the G2/M cell cycle phase [51],
but for Jurkat cells the arrest of proliferation induced by
onconase could not be attributed to alterations in the
cell cycle phase progression [52].
The effects of PE5 on NCI/ADR-RES cells are clearly
different to those induced by the treatment with onco-
nase. The cell cycle phase distribution and the proportion
of cells at early and late apoptosis are very different. On
the other hand, treatment with onconase decreases
three-fold the concentration of XIAP respective to
untreated cells whereas it does not change the level of
the phosphorylated form of JNK. In this sense, onconase
and PE5 seem to be bypassing different mechanisms of
survival, mediated by XIAP and JNK, respectively. These
results are very indicative that both RNases kill the cells
through different mechanisms of apoptosis. The different
mechanisms are likely related to their mechanism of
action. Onconase is driven into the cytoplasm and its
natural substrates are t-RNA and most probably the non-
coding RNA (microRNA) [53] whereas PE5 is located in
the nucleolus [10] and targets nuclear RNA [12]. Inter-
estingly, nucleolus and biogenesis of rRNA are important
factors distinguishing cancer from normal cells and may
have an active role in tumorigenesis [54]. Altogether,
makes the use of both RNases in combination as che-
motherapeutical agents very attractive.
Conclusions
We have demonstrated that PE5 does not arrest cell
proliferation but rather induces cell death by apoptosis.
Figure 5 Caspase-3, -8 and -9 activities in NCI/ADR-RES cells
treated with PE5 or onconase. Cells were treated with 35 μM PE5
or 5 μM onconase (ONC) for 24 (black bars), 48 (striped bars) and
72 h (checkered bars). White bars indicate untreated cells (control).
Parallel samples were treated with the specific inhibitors of
caspase-3 (z-DEVD-FMK), caspase-8 (z-IETD-FMK), caspase-9
(z-LEHD-FMK) (stippled bars) as a negative control. Activation of
caspase-3, -8 and -9 was quantified in whole cell lysates using a
quantitative colorimetric assay as described in the text. Results are
expressed as the mean ± SE of three independent experiments.
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Page 9 of 12We show that the cytotoxicity of PE5 is associated by
the increase of the expression of p21
WAF1/CIP1 together
with the underphosphorylation of JNK. We also show
that the mechanism of cytotoxicity of PE5 is different to
that induced by the onconase. In vivo experiments with
PE5 are warranted in order to evaluate its anticancer
capacity.
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